There has been limited progress in developing reliable therapeutic interventions for spinal cord injury (SCI). Currently, treatments rely on stabilization and decompression of the spinal cord to restore mechanical homeostasis immediately following injury and controlling secondary complications. While advances in surgical and medical techniques have certainly improved this outlook, limitations in functional recovery continue to impede clinically significant improvements. These limitations are dependent on evolving immunological mechanisms that shape the cellular environment at the site of SCI. In this review, we examine these mechanisms, identify relevant cellular components, and discuss emerging treatments in stem cell grafts and adjuvant immunosuppressants that target these pathways. As the field advances, we expect that stem cell grafts and these adjuvant treatments will significantly shift therapeutic approaches to acute SCI with the potential for more promising outcomes.

Immunological Response in CNS Injury

Although the peripheral nervous system has a robust system for regeneration and healing following injury, the CNS is thought to be more limited. The CNS was once thought to be an immune-privileged site due to protective barriers; however, it is now known that immune cells are recruited to sites of injury to mediate scar formation and tissue recovery. Relevant to our discussion is the concept of axonal regeneration. Significant advances in recreating the complex connections underlying the central nervous system (CNS) following SCI provide a potential therapeutic approach with numerous benefits. In this review, we will examine the immunological mechanisms dictating scar formation following SCI and prospective therapeutic interventions currently being evaluated for use in patients.

Immunosuppressive mechanisms for stem cell transplant survival in spinal cord injury

*Joseph P. Antonios, PhD,1 Ghassan J. Farah, BS,2 Daniel R. Cleary, MD, PhD,2 Joel R. Martin, MD,2 Joseph D. Ciacci, MD,2 and Martin H. Pham, MD2

1David Geffen School of Medicine, University of California, Los Angeles, Los Angeles; and 2Department of Neurosurgery, University of California San Diego School of Medicine, San Diego, California

Spinal cord injury (SCI) has been associated with a dismal prognosis—recovery is not expected, and the most standard interventions have been temporizing measures that do little to mitigate the extent of damage. While advances in surgical and medical techniques have certainly improved this outlook, limitations in functional recovery continue to impede clinically significant improvements. These limitations are dependent on evolving immunological mechanisms that shape the cellular environment at the site of SCI. In this review, we examine these mechanisms, identify relevant cellular components, and discuss emerging treatments in stem cell grafts and adjuvant immunosuppressants that target these pathways. As the field advances, we expect that stem cell grafts and these adjuvant treatments will significantly shift therapeutic approaches to acute SCI with the potential for more promising outcomes.


KEYWORDS spinal cord injury; stem cell grafts; immunosuppressants; glial scar
The importance of the immune system in mediating tissue recovery following CNS injury cannot be understated. The primary response to injury is mediated by neutrophils, the most abundant immune cells in the body. Myeloperoxidase, released by these neutrophils, is a peroxidase enzyme within neutrophilic granules that serves to damage host tissue via generation of highly reactive oxygen species. Studies have shown that inhibition of neutrophils alone at the site of SCI helps with recovery. Within 72 hours of injury, ependymal stem/progenitor cells (epSPCs), which are adult multipotent stem cells that differentiate into both neural and glial cells, are activated. These cells then migrate from the spinal central canal to the site of injury. A majority of epSPCs then differentiate into astrocytes, and a small portion differentiate into myelin-producing oligodendrocytes. 

Astrocytes recruit macrophages, which then restrict axonal growth, mediate the inflammatory response, and limit the extent of SCI. There is a preponderance of inhibitory molecules released by astrocytes within the forming glial scar. One of these, MCP-1, promotes recruitment of M1 proinflammatory macrophages directly to the site of injury via CCR2 receptors. These macrophages, acting via release of tumor necrosis factor α (TNF-α) and inducible nitric oxide synthase (iNOS), are associated with inhibiting neuronal axon growth in the spinal cord. Specifically, TNF-α is a cytokine that increases local concentrations of caspases, resulting in cell apoptosis. Further, iNOS promotes apoptosis of damaged neurons. While this may be beneficial acutely, it results in apoptosis of healthy neurons and inhibition of regrowth and regeneration of axonal connections over a chronic period.

These intrinsic immunological mechanisms are useful in limiting the extent of injury acutely and preventing further damage to the CNS. However, their utility quickly becomes detrimental to neurological recovery following this initial phase—these same factors prevent formation of new neuronal growth, axonal regeneration, and the formation of functional connections in the CNS. As studies have further elucidated these mechanisms, new avenues for therapeutic intervention through the inhibition and modulation of these immunological responses have become paramount.

Chondroitinase ABC is a bacterial enzyme developed to digest chondroitin sulfate proteoglycans by catalyzing removal of associated sulfate-glycosaminoglycan chains. This promotes M2 macrophage phenotype at the site of SCI. Other therapies have targeted TNF-α directly. Epigallocatechin gallate lowers TNF-α levels, resulting in decreased neuronal death and promoting repair mechanisms. TNF-α antagonists such as etanercept promote stem cell viability and increase functional recovery.

**Preclinical Studies Evaluating Immunotherapeutic Adjuvants to Stem Cell Transplantation**

The efficacy of these grafts appears to be limited by the inhibitory mechanisms outlined above. There is considerable interest in developing immunological therapeutics to target these mechanisms. Specifically, tacrolimus and cyclosporine have emerged as promising potential adjuvants, enhancing graft survival and recovery following SCI.

**Tacrolimus**

Tacrolimus (also known as FK506) is an immunosuppressive drug of choice that is often administered as a monotherapy or in a multi-drug regimen along with other immunosuppressants with different mechanisms of action. The mechanism by which tacrolimus induces immunosuppression is primarily through inhibition of T-lymphocyte proliferation. Tacrolimus binds the FK506 binding protein (FKBP), thus inhibiting the peptidyl-prolyl cis-trans isomerase activity of FKBP. Though the exact function of FKBP, an immunophilin, is not clear with respect to T-lymphocyte activation, formation of a pentameric complex between tacrolimus, FKBP, calcineurin A, calcineurin B, and calmodulin is known to inhibit the phosphatase activity of calcineurin. Dephosphorylation of the family of NFAT transcription factors by calcineurin normally allows NFAT translocation into the nucleus, where it increases transcription of genes required for T-cell activation and proliferation. Tacrolimus is commercialized in more than 70 countries and is currently the drug of choice for immunosuppression following transplantation procedures, including heart, kidney, liver, and bone marrow transplants. Vicari-Christensen et al. demonstrated...
that tacrolimus prolongs survival in patients receiving solid organ transplants, and critically, exhibits tolerable adverse effects. Numerous studies over the past decade have attempted to apply the immunosuppressive qualities of tacrolimus to prevent the rejection of allogeneic stem cell transplantation into spinal cord lesions (Table 1).

In 2013, Sevc et al. demonstrated the safety and efficacy of subcutaneously delivered tacrolimus formulations in promoting graft survival following SCI in a rat model. Sevc et al. demonstrated that a dose of 4.9 mg/kg/day of tacrolimus, administered through a subcutaneous pellet, allowed for graft survival in L3 spinal contusion models. The spinal graft was characterized by advanced neuronal maturation, neurons that had migrated outside of the grafts, and only the occasional presence of lymphocytic infiltration. In an effort to confirm the role of immunosuppression in the success of the graft, human fetal spinal cord stem cells (hSSCs) were then grafted in the absence of immunosuppression. The resultant spinal cord showed complete graft rejection with significant lymphocytic infiltration. Itakura et al. corroborated these findings by showing that immunosuppression with tacrolimus monotherapy significantly improved xenograft survival in mice. At 28 days post-transplant, the graft survival rate was 82% in mice treated with daily subcutaneous injections of 5 mg/kg tacrolimus. This was compared to a 0% graft survival rate at 28 days for immunocompetent mice without immunosuppression.

Similarly, Torres-Espín et al. showed that intraperitoneal administration of tacrolimus following the engraftment of mesenchymal stem cells at the site of SCI was associated with improved graft survival. Mesenchymal stem cells (MSCs) have been shown to modulate the host inflammatory response, increase tissue sparing, and support axonal recovery. Nevertheless, MSC grafts in immunocompetent hosts have exhibited only marginal recovery of motor and sensory function following SCI. In models that received both high-dose and low-dose MSC grafts following T8–9 spinal contusion injury, immunosuppression through intraperitoneal tacrolimus significantly improved late graft survival at 21 and 42 days postprocedure. In contrast, the functional recovery was only slightly improved in the presence of tacrolimus immunosuppression, with no significance demonstrated between immunosuppressed and non-immunosuppressed groups. Injection of human iPSC-NPCs into C57BL/6 mice with moderately

<table>
<thead>
<tr>
<th>Study</th>
<th>Model/Subjects</th>
<th>Injury</th>
<th>Transplant Cell Type</th>
<th>Immunosuppressant Regimen</th>
<th>Graft Survival</th>
<th>Motor Function Recovery</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sevc et al., 2013</td>
<td>Animal SD rats</td>
<td>L3 contusion</td>
<td>HUES7-NPCs</td>
<td>Tacrolimus + MMF (SC): 1st 14 days following transplant; tacrolimus (SC): after day 14, varying doses</td>
<td>Yes, sig impr w/ immunosuppression</td>
<td>NR</td>
</tr>
<tr>
<td>Torres-Espín et al., 2015</td>
<td>Animal SD rats</td>
<td>T8–9 contusion</td>
<td>MSCs</td>
<td>Tacrolimus (IP): 2 mg/kg bolus immediately following inj + 1 mg/kg daily until end of FU</td>
<td>Yes, sig impr w/ immunosuppression</td>
<td>Slight impr w/ immunosuppression (not sig)</td>
</tr>
<tr>
<td>Pomeschik et al., 2015</td>
<td>Animal C57BL/6 mice</td>
<td>T10 contusion</td>
<td>hiPSC-NPCs</td>
<td>Tacrolimus (IP): daily 2 mg/kg bolus</td>
<td>Poor long-term survival</td>
<td>No impr w/ stem cell inj (compared to control)</td>
</tr>
<tr>
<td>Itakura et al., 2015</td>
<td>Animal Adult female common marmosets</td>
<td>C5 contusion</td>
<td>ESC-derived NS/PCs</td>
<td>Tacrolimus (SC): 1 mg/kg/day</td>
<td>Yes</td>
<td>Improv w/ stem cell inj (compared to control)</td>
</tr>
<tr>
<td>van Gorp et al., 2015</td>
<td>Animal C57BL/6 H-2kb mice</td>
<td>None</td>
<td>Human GBM cell line U251 MG</td>
<td>Tacrolimus (SC): 5 mg/kg/day</td>
<td>Yes, sig impr w/ immunosuppression</td>
<td>NR</td>
</tr>
<tr>
<td>Itakura et al., 2015</td>
<td>Animal C57BL/6 H-2kb mice</td>
<td>None</td>
<td>Human GBM cell line U251 MG</td>
<td>Tacrolimus (SC): 1.5 mg/kg BID; MMF (SC): 30 mg/kg/day for days 0–10; methylprednisolone acetate (IM): varied dosing</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Li et al., 2015</td>
<td>Animal C57BL/6 WT mice</td>
<td>C4 contusion</td>
<td>hiPS-C-derived astrocytes</td>
<td>Tacrolimus (SC): 1 mg/kg/day; anti-CD4 mAb (SC): 10 mg/kg/day</td>
<td>Sig impr w/ immunosuppression</td>
<td>NR</td>
</tr>
<tr>
<td>Rosenzweig et al., 2018</td>
<td>Animal Adult male rhesus monkeys</td>
<td>Rt C7 hemisection</td>
<td>Human spinal cord–derived NPCs</td>
<td>Tacrolimus: varying doses + MMF: varying doses</td>
<td>Yes, impr w/ increased doses of immunosuppression</td>
<td>Yes, impr w/ increased doses of immunosuppression</td>
</tr>
</tbody>
</table>

BID = twice daily; FU = follow-up; GBM = glioblastoma multiforme; hiPSC-NPCs = human iPSC-NPCs; IM = intramuscular; impr = improvement; inj = injection; IP = intraperitoneal; mAb = monoclonal antibody; MMF = mycophenolate mofetil; NR = not reported; NS/PCs = neural stem/progenitor cells; SC = subcutaneous; SD = Sprague-Dawley; sig = significant; WT = wild-type.
contused SCI has also failed to improve locomotor testing in the presence of intraperitoneal tacrolimus immunosuppression. However, in this case there was also poor graft survival, which is a likely explanation for the absence in functional recovery.

Other studies have successfully been able to demonstrate improved graft survival in conjunction with functional recovery following SCI. Iwai et al. showed that embryonic stem cell–derived neural stem/progenitor cells grafted into C5 contused adult female common marmosets exhibited significant improvement in motor function of upper extremities as well as open-field locomotion. In the presence of tacrolimus immunosuppression, stem cell grafting showed significant improvement in open-field testing 4 weeks post-transplant, and significant improvement on grip strength test 9 weeks post-transplant. This recovery in motor function was accompanied by immunohistochemical confirmation of graft cell survival that migrated extensively into both gray and white matter at the lesion epicenter.

The enhancement of immunosuppression through the use of multiple drug therapies with different targets may allow for improved graft survival. Itakura et al. demonstrated a 100% graft survival rate at 28 days following intraspinal stem cell transplantation of mice immunosuppressed with a combination of tacrolimus and anti-CD4 monoclonal antibody. As mentioned above, only an 82% graft survival rate was achieved in mice immunosuppressed with tacrolimus alone. Along similar lines, Li et al. was successful in demonstrating robust graft survival in human iPSC–derived astrocyte engraftment in the presence of tacrolimus and rapamycin, an mTOR inhibitor.

In 2013, van Gorp et al. used the combination of tacrolimus, mycophenolate mofetil, and methylprednisolone as immunosuppressive therapy following hSSC transplantation into L3 compression injury in Sprague-Dawley rats. Immunohistochemical examination of graft cell survival that migrated extensively into both gray and white matter at the lesion epicenter.

The variation in functional recovery outcomes among the two studies is likely due to the difference in stem cells grafted and animal models used. Similar to their results with tacrolimus immunosuppression, Li et al. also demonstrated robust graft survival of human iPSC–derived astrocytes in a C4 contusion model.

Despite some success of graft survival in stem cell transplantation with cyclosporine-mediated immunosuppression, other studies have demonstrated a weak or absent effect of cyclosporine immunosuppression on stem cell graft survival. Sparling et al. transplanted skin-derived precursor Schwann cells (SKP-SCs) into a C4–5 DLF lesion rat model. Comparison of the cyclosporine-immunosuppressed and non-immunosuppressed groups showed no significant difference on parameters including limb motor function, forelimb EMG, and immunohistochemical analysis of graft survival. These results may indicate that the immune response against the grafted SKP-SCs was not T cell mediated, and thus cyclosporine was not protective for the graft. Another study that showed no effect of cyclosporine immunosuppression in the grafting of SKP-SCs into a T8 hemisection rat model supports the hypothesis that a T-cell–mediated immune response may not be involved.

In addition to the lack of effect by cyclosporine administration, transplantation of the SKP-SCs into rats of a different strain than the donor yielded similar graft survival as the strain matched models. This finding further corroborates the theory that immunosuppression, specifically by cyclosporine, would not be beneficial in SKP-SC transplantation. Hodgetts et al. also demonstrated a null effect of cyclosporine-mediated immunosuppression on the success of mesenchymal precursor cell injection into T9–10 athymic nude rats. A logical explanation for the absence of effect in this case is that the athymic nude rats were already T cell deficient, and thus their immune response against the graft was mediated by mechanisms not affected by cyclosporine activity.

Human iPSC engraftment into a T8–9 compression injury rat model in the presence of cyclosporine, azathioprine sodium, and methylprednisolone has demonstrated success. Human iPSCs exhibited robust survival in the

Ciclosporine

Ciclosporine (also known as cyclosporine A or CsA), another potential immunosuppressant commonly employed to prevent allograft rejection and graft versus host disease, functions to inhibit T-cell activation. Similar to the mechanism of tacrolimus, ciclosporine inhibits the transcription of IL-2 by activated T cells through inhibition of calcineurin-mediated dephosphorylation of NFAT. Ciclosporine binds cyclophilins with high affinity, and this cyclophilin-ciclosporine is able to associate with calcineurin to prevent its activity. Ciclosporine has been utilized in numerous studies as a possible mechanism of immunosuppression to prevent rejection of stem cell allograft procedures following SCI (Table 2).

In 2013, Nutt et al. reported the use of daily subcutaneous ciclosporine injections following transplantation of human induced pluripotent stem cells (hiPSCs) in the C4 contusion injury rat model. Immunofluorescence indicated significant survival and differentiation of grafted stem cells at 8 weeks post-transplant. This result, however, lacked an association with functional recovery. Assessment of the forelimb reaching task and the limb-use asymmetry test demonstrated no significant improvement.

In contrast, Oh et al. achieved increased graft survival and improved functional recovery following intraspinal disc-derived iPSC graft into T11 compression injury mice in the presence of daily ciclosporine immunosuppression. The enhancement of immunosuppression through the use of multiple drug therapies with different targets may allow for improved graft survival. Itakura et al. demonstrated a 100% graft survival rate at 28 days following intraspinal stem cell transplantation of mice immunosuppressed with a combination of tacrolimus and anti-CD4 monoclonal antibody. As mentioned above, only an 82% graft survival rate was achieved in mice immunosuppressed with tacrolimus alone. Along similar lines, Li et al. was successful in demonstrating robust graft survival in human iPSC–derived astrocyte engraftment in the presence of tacrolimus and rapamycin, an mTOR inhibitor. In 2013, van Gorp et al. used the combination of tacrolimus, mycophenolate mofetil, and methylprednisolone as immunosuppressive therapy following hSSC transplantation into L3 compression injury in Sprague-Dawley rats. Immunohistochemical examination of graft cell survival that migrated extensively into both gray and white matter at the lesion epicenter.

The enhancement of immunosuppression through the use of multiple drug therapies with different targets may allow for improved graft survival. Itakura et al. demonstrated a 100% graft survival rate at 28 days following intraspinal stem cell transplantation of mice immunosuppressed with a combination of tacrolimus and anti-CD4 monoclonal antibody. As mentioned above, only an 82% graft survival rate was achieved in mice immunosuppressed with tacrolimus alone. Along similar lines, Li et al. was successful in demonstrating robust graft survival in human iPSC–derived astrocyte engraftment in the presence of tacrolimus and rapamycin, an mTOR inhibitor. In 2013, van Gorp et al. used the combination of tacrolimus, mycophenolate mofetil, and methylprednisolone as immunosuppressive therapy following hSSC transplantation into L3 compression injury in Sprague-Dawley rats. Immunohistochemical analysis and MRI volume reconstruction depicted near-complete filling of the injury cavity as well as the formation of putative GABA-ergic synapses between host and grafted neurons. Additionally, significant recovery of motor and sensory function was exhibited in these rats. A similar immunosuppressive therapy has proven successful in nonhuman primates. The dosage of mycophenolate mofetil, an inosine monophosphate (IMP) dehydrogenase inhibitor, and tacrolimus following injection of neural progenitor cells into the C7 hemisection lesion site of marmosets seemed to influence the outcomes of the procedure. At low doses, no or minimal graft survival was demonstrated 2 months postoperatively. Escalation of the dosage of both mycophenolate mofetil and tacrolimus in addition to increased monitoring of serum immunosuppressant drug levels exhibited robust graft survival and filling of the lesion site.

Ciclosporine

Ciclosporine (also known as cyclosporine A or CsA), another potential immunosuppressant commonly employed to prevent allograft rejection and graft versus host disease, functions to inhibit T-cell activation. Similar to the mechanism of tacrolimus, ciclosporine inhibits the transcription of IL-2 by activated T cells through inhibition of calcineurin-mediated dephosphorylation of NFAT. Ciclosporine binds cyclophilins with high affinity, and this cyclophilin-ciclosporine is able to associate with calcineurin to prevent its activity. Ciclosporine has been utilized in numerous studies as a possible mechanism of immunosuppression to prevent rejection of stem cell allograft procedures following SCI (Table 2).

In 2013, Nutt et al. reported the use of daily subcutaneous ciclosporine injections following transplantation of human induced pluripotent stem cells (hiPSCs) in the C4 contusion injury rat model. Immunofluorescence indicated significant survival and differentiation of grafted stem cells at 8 weeks post-transplant. This result, however, lacked an association with functional recovery. Assessment of the forelimb reaching task and the limb-use asymmetry test demonstrated no significant improvement.

In contrast, Oh et al. achieved increased graft survival and improved functional recovery following intraspinal disc-derived iPSC graft into T11 compression injury mice in the presence of daily ciclosporine immunosuppression. The variation in functional recovery outcomes among the two studies is likely due to the difference in stem cells grafted and animal models used. Similar to their results with tacrolimus immunosuppression, Li et al. also demonstrated robust graft survival of human iPSC–derived astrocytes in a C4 contusion model.

Despite some success of graft survival in stem cell transplantation with ciclosporine-mediated immunosuppression, other studies have demonstrated a weak or absent effect of ciclosporine immunosuppression on stem cell graft survival. Sparling et al. transplanted skin-derived precursor Schwann cells (SKP-SCs) into a C4–5 DLF lesion rat model. Comparison of the ciclosporine-immunosuppressed and non-immunosuppressed groups showed no significant difference on parameters including limb motor function, forelimb EMG, and immunohistochemical analysis of graft survival. These results may indicate that the immune response against the grafted SKP-SCs was not T cell mediated, and thus ciclosporine was not protective for the graft. Another study that showed no effect of ciclosporine immunosuppression in the grafting of SKP-SCs into a T8 hemisection rat model supports the hypothesis that a T-cell–mediated immune response may not be involved.

In addition to the lack of effect by ciclosporine administration, transplantation of the SKP-SCs into rats of a different strain than the donor yielded similar graft survival as the strain matched models. This finding further corroborates the theory that immunosuppression, specifically by ciclosporine, would not be beneficial in SKP-SC transplantation. Hodgetts et al. also demonstrated a null effect of ciclosporine-mediated immunosuppression on the success of mesenchymal precursor cell injection into T9–10 athymic nude rats. A logical explanation for the absence of effect in this case is that the athymic nude rats were already T cell deficient, and thus their immune response against the graft was mediated by mechanisms not affected by ciclosporine activity.

Human iPSC engraftment into a T8–9 compression injury rat model in the presence of ciclosporine, azathioprine sodium, and methylprednisolone has demonstrated success. Human iPSCs exhibited robust survival in the
Clinical Applications of Immunotherapeutic Adjuvants to Stem Cell Transplantation

Several clinical trials have been performed to assess the safety of stem cell engraftment in patients with SCI. Geffner et al. and Mendonca et al., in their respective phase I studies, demonstrated that transplantation of autologous stem cells is safe and feasible, with potential for neurological improvement.12,34 Ongoing phase I/II clinical trials continue to further assess stem cell transplantation (NCT02326662, NCT03505034, and NCT02687672).

While these trials examine stem cell transplantation alone for SCI, there have been a limited number of studies further investigating the combination of transplantation with adjuvant immune therapies (Table 3).

The combination therapy of basiliximab (an anti–IL-2 receptor monoclonal antibody), mycophenolate mofetil, and tacrolimus has previously been used successfully in a phase I trial for intraspinal transplantation of stem cells in amyotrophic lateral sclerosis (ALS) patients.13 Curtis et al. used this combination therapy in a phase I study for

### TABLE 3. Clinical applications: summary of clinical trials examining stem cell transplantation with adjuvant treatments

<table>
<thead>
<tr>
<th>Authors &amp; Year</th>
<th>Study Type</th>
<th>Model/Subjects</th>
<th>Injury</th>
<th>Transplant Cell Type</th>
<th>Immunosuppressant Regimen</th>
<th>Graft Survival</th>
<th>Motor Function Recovery</th>
</tr>
</thead>
<tbody>
<tr>
<td>Curtis et al., 2018</td>
<td>Phase I study</td>
<td>Pts w/ SCI</td>
<td>T2–12 SCI</td>
<td>Human spinal cord–derived neural stem cells (NSI-566)</td>
<td>Basiliximab (IV): 20 mg during transplant &amp; POD 4; tacrolimus (PO): BID to maintain level of 4–8 ng/mL; MMF (PO): dose escalation starting at 500 mg BID</td>
<td>NR</td>
<td>Yes (no statistical power)</td>
</tr>
<tr>
<td>Levi et al., 2018</td>
<td>Phase II study</td>
<td>Pts w/ chronic SCI</td>
<td>C5–7 tetraplegia</td>
<td>Human CNS stem cells</td>
<td>Tacrolimus (PO): monitored blood levels (5–10 μg/L for 1st 28 days, 2–5 μg/L for following 5 mos); TMP: 6 mos; MMF: 1 mo; dexamethasone + pantoprazole: day before + 7 days after transplantation</td>
<td>NR</td>
<td>Yes</td>
</tr>
</tbody>
</table>

POD = postoperative day; pts = patients; RCT = randomized controlled trial; TMP = trimethoprim-sulfamethoxazole.
the transplantation of human spinal cord–derived neural stem cells into four subjects with T2–12 SCI. At 18–27 months postcell delivery, no significant adverse effects were noted. Subjects showed functional change, including new voluntary muscle activity at or below the level of the lesion, robust EMG changes exhibiting previously unrecorded muscle activity, and potential improvement from status of “complete” to “incomplete” SCI. Nevertheless, as a phase I study that successfully demonstrated the safety of the procedure and subsequent immunosuppression, the functional improvements lacked statistical power and require further investigation.

In a phase II single-blind randomized controlled trial, Levi et al. tested the efficacy of human neural stem cell transplantation into the cervical spinal cord of patients with chronic C5–7 tetraplegia. Immunosuppression was achieved through a therapeutic combination of tacrolimus, trimethoprim-sulfamethoxazole, and mycophenolate mofetil. In addition to demonstrating safety at all stem cell doses administered, the study reported improved upper extremity motor scores compared to controls.

Conclusions
Considerable resources have been poured into the development of novel strategies for SCI therapy—improvement in surgical strategies, refinement of corticosteroid regimens, and more recently, stem cell graft treatment. However, the same immunological factors that produce the glial scar and limit functional recovery also inhibit stem cell differentiation, migration, and growth at the site of injury. Studies have demonstrated the utility of immunosuppressive therapies to limit these factors and promote stem cell graft survival and maintenance. These therapies are promising and they demonstrate the potential for development of a standard clinical application for patients with SCI.

References
24. Kubota K, Sawai H, Kumamaru H, Maeda T, Ohkawa Y,
54. Vidal PM, Lemmens E, Geboes L, Vanganswinkel T, Ne-lissen S, Hendrix S: Late blocking of peripheral TNF-α is ineffective after spinal cord injury in mice. *Immunobiology 218*:281–284, 2013

Disclosures
The authors report no conflict of interest concerning the materials or methods used in this study or the findings specified in this paper.

Author Contributions
Conception and design: Pham, Antonios, Farah, Cleary, Martin. Analysis and interpretation of data: Antonios, Farah. Drafting the article: Pham, Antonios, Farah. Critically revising the article: Pham, Antonios, Cleary, Ciacci. Reviewed submitted version of manuscript: Pham, Antonios, Martin, Ciacci.

Correspondence
Martin H. Pham: University of California San Diego School of Medicine, San Diego, CA. mhpham@ucsd.edu.